GOVX (Geovax Labs) Accounts Payable: $1.43 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GOVX Geovax Labs Inc GOVX
22 GF Score
Price $0.98
! 3 Warning Signs
View Full Analysis

What is Geovax Labs Accounts Payable?

Geovax Labs GOVX +11.28% 22 Accounts Payable is $1.43 Mil as of Mar. 2026. GuruFocus rates GOVX with a GF Score™ of 22/100. The stock has 3 warning signs investors should review.

Geovax Labs's Accounts Payable for the quarter that ended in Mar. 2026 was $1.43 Mil.

Geovax Labs's quarterly Accounts Payable declined from Sep. 2025 ($0.98 Mil) to Dec. 2025 ($0.79 Mil) but then increased from Dec. 2025 ($0.79 Mil) to Mar. 2026 ($1.43 Mil).

Geovax Labs's annual Accounts Payable declined from Dec. 2023 ($2.80 Mil) to Dec. 2024 ($1.85 Mil) and declined from Dec. 2024 ($1.85 Mil) to Dec. 2025 ($0.79 Mil).

Geovax Labs Accounts Payable Historical Data

* Premium members only.

The historical data trend for Geovax Labs's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Geovax Labs Accounts Payable Chart

Geovax Labs Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.06 1.75 2.80 1.85 0.79

Geovax Labs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 1.83 0.98 0.79 1.43
GOVX
22GF Score
Geovax Labs Inc GOVX
Accounts Payable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Geovax Labs Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $1.43 Mil mean?
Geovax Labs (GOVX) has a Accounts Payable of $1.43 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Geovax Labs and its competitors.
Is Geovax Labs' Accounts Payable too high?
Geovax Labs' current Accounts Payable is $1.43 Mil. Overall, Geovax Labs has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Geovax Labs' Accounts Payable compare to XBIO and MTVA?
Geovax Labs' Accounts Payable of $1.43 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Geovax Labs and its competitors. Geovax Labs's current Accounts Payable is $1.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Geovax Labs stock overvalued right now?
Geovax Labs (GOVX) has a current Accounts Payable of $1.43 Mil. The current Accounts Payable is $1.43 Mil. Geovax Labs' overall GF Score™ is 22/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Geovax Labs (GOVX), the current Accounts Payable is $1.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Geovax Labs Business Description

Address 1955 Lake Park Drive, Suite 300, Smyrna, GA, USA, 30080
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. The company is focused on the advancement of GEO-MVA, a Modified Vaccinia Ankara (MVA) vaccine candidate for mpox, smallpox, and other poxviruses. Its flagship clinical program in oncology is Gedeptin, a novel oncolytic solid tumor gene-directed therapy, which recently completed a multicenter Phase 1/2 clinical trial for head and neck cancers. The company is also developing GEO-CM04S1, a next-generation multi-antigen COVID-19 vaccine, which is currently being evaluated in two Phase 2 clinical trials.
22GF Score

Get the complete analysis for GOVX

Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.98
Price